Windlas Biotech Q2 Results FY27: PAT Rises 1.4% to Rs 18.05 Cr, Revenue Rs 263.91 Cr
- November 5, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Windlas Biotech Q2 Results FY27 were declared on 5 November 2026 on a standalone basis. The quarterly results show revenue of Rs 263.91 Cr against Rs 222.4 Cr in the same quarter last year, a YoY growth of 18.66%. Net profit was Rs 18.05 Cr against Rs 17.8 Cr, up 1.4%, while Operating Profit stood at Rs 29.37 Cr.
Windlas Biotech Ltd (WINDLAS) Q2 Results FY27 announced on 5 November 2026, covering the company’s financial performance for the July to September quarter. The results date brought standalone revenue of Rs 263.91 Cr and PAT of Rs 18.05 Cr, and Windlas Biotech Q2 Results FY27 are shown on the standalone results basis against the July to September 2025 quarter.
This Windlas Biotech Q2 Results results analysis covers the financial highlights, the business factors, the outlook and the risks. The section below places revenue, Operating Profit and net profit next to the figures for the same quarter a year earlier.
Click Here – Get Free Investment Predictions
Windlas Biotech Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 263.91 Cr | Rs 222.4 Cr | +18.66% YoY |
| Operating Profit | Rs 29.37 Cr | Rs 28.56 Cr | +2.84% YoY |
| Net Profit (PAT) | Rs 18.05 Cr | Rs 17.8 Cr | +1.4% YoY |
Source: company filing for Windlas Biotech Q2 Results FY27, 5 November 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Windlas Biotech Q2 Results: What Stands Out
- Revenue of Rs 263.91 Cr was reported for the quarter, against Rs 222.4 Cr a year earlier, which is a YoY growth of 18.66%.
- Net profit of Rs 18.05 Cr compares with Rs 17.8 Cr in the same quarter last year, a rise of 1.4% year on year.
- Operating Profit of Rs 29.37 Cr compares with Rs 28.56 Cr a year earlier, a YoY growth of 2.84% on the standalone results basis.
- Windlas Biotech Q2 Results FY27 show all three headline lines higher than in the July to September 2025 quarter.
- The risk list in the filing data covers the narrower margin and the return ratios, and the performance analysis below comes first.
Windlas Biotech Q2 Results FY27: Performance Analysis
Standalone figures show that revenue, Operating Profit and net profit all moved higher year on year in the quarter ended September 2026. Revenue rose 18.66% to Rs 263.91 Cr, Operating Profit rose 2.84% to Rs 29.37 Cr and net profit rose 1.4% to Rs 18.05 Cr, all on a standalone basis.
In this Windlas Biotech Q2 Results FY27 results analysis, revenue grew much faster than the profit lines, since the 18.66% rise compares with a 2.84% rise in Operating Profit and a 1.4% rise in net profit. The supplied data confirms these figures but does not establish a specific cause for the gap.
For the Windlas Biotech Q2 Results quarter, the absolute figures are also visible: revenue is higher by the difference between Rs 222.4 Cr and Rs 263.91 Cr, while net profit moved from Rs 17.8 Cr to Rs 18.05 Cr. Investors will next follow the quarterly results disclosures, which is where the business factors come in.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The business factors behind the quarterly results begin with the top line. Revenue grew 18.7% year on year to Rs 263.91 Cr in the latest quarter, from Rs 222.4 Cr in the same quarter a year earlier, on a standalone basis.
Net Profit Growth – Net profit rose 1.4% year on year to Rs 18.05 Cr, compared with Rs 17.8 Cr a year earlier. In Windlas Biotech Q2 Results FY27, this profit line grew by a smaller percentage than revenue, which links the bottom line to the sales figure above.
Consecutive Revenue Growth – Revenue has risen in each of the last 4 quarters. The latest figure of Rs 263.91 Cr therefore continues a run of sequential increases reported in the quarterly results data.
FY27 Outlook After Windlas Biotech Q2 Results
The business factors lead into the outlook, where the results analysis rests on the figures declared for the quarter. The company reported net profit of Rs 18.05 Cr for July to September 2026, and the full FY27 picture will depend on the numbers reported in the quarters that follow.
In Windlas Biotech Q2 Results FY27, the YoY direction is higher on all three lines, so the next standalone filings will show whether that pattern holds. Investors can track revenue, Operating Profit and net profit on Univest, and the risks below show what to watch alongside them.
Key Risks to Watch After Windlas Biotech Q2 Results FY27
Narrower Net Profit Margin
Net profit margin narrowed to 6.8% from 8.0% in the comparison quarter. After Windlas Biotech Q2 Results FY27, this margin remains a number investors can follow in later filings, since revenue grew faster than net profit.
Return on Capital Employed
Return on capital employed declined to 16.06% in FY26 from 17.12% in FY25. This is a full year measure, so it sits apart from the quarter’s YoY growth but remains part of the picture investors weigh.
Return on Equity
Return on equity of 12.52% in FY26 is below 15%. Together with the return on capital employed, it frames the conclusion that investors draw from the quarterly results.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Windlas Biotech Q2 Results FY27 show standalone revenue of Rs 263.91 Cr, Operating Profit of Rs 29.37 Cr and net profit of Rs 18.05 Cr, all higher year on year. These quarterly results come with margin and return risks that investors can follow through the standalone results on Univest. Consult a SEBI-registered advisor before acting on this Windlas Biotech Q2 Results analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Windlas Biotech Q2 Results FY27
What are Windlas Biotech Q2 Results FY27?
Ans. Windlas Biotech Q2 Results FY27 cover the July to September 2026 quarter on a standalone basis, with revenue of Rs 263.91 Cr. The Financial Highlights table compares each line with the same quarter last year.
What is the results date for Windlas Biotech Q2 Results FY27?
Ans. The results date for Windlas Biotech Q2 Results FY27 is 5 November 2026, when the company declared its numbers for the quarter. This date appears in the Quick Answer and the opening paragraphs.
What revenue was reported in Windlas Biotech Q2 Results FY27?
Ans. Windlas Biotech reported revenue of Rs 263.91 Cr in the quarter, compared with Rs 222.4 Cr a year earlier. This comparison is shown in the Financial Highlights table and the Performance Analysis section.
What net profit was reported in Windlas Biotech Q2 Results FY27?
Ans. Net profit in the quarter was Rs 18.05 Cr, against Rs 17.8 Cr in the same quarter last year. The Key Takeaways section lists this figure alongside revenue and Operating Profit for quick reading.
How much YoY growth did revenue show in Windlas Biotech Q2 Results FY27?
Ans. Revenue showed YoY growth of 18.66% in the quarter, rising from Rs 222.4 Cr to Rs 263.91 Cr. The Performance Analysis section compares this with the 1.4% rise in net profit.
Did net profit rise or fall in Windlas Biotech Q2 Results?
Ans. Net profit rose in the quarter by 1.4% year on year, from Rs 17.8 Cr to Rs 18.05 Cr. The Key Business Factors section explains how this compares with the growth in revenue.
What was the Operating Profit in Windlas Biotech Q2 Results FY27?
Ans. Operating Profit was Rs 29.37 Cr in the quarter, up 2.84% from Rs 28.56 Cr a year earlier. This line is covered in the Performance Analysis section alongside revenue and net profit.
Are Windlas Biotech Q2 Results consolidated results or standalone results?
Ans. The results are standalone results, covering Windlas Biotech as a single company for the quarter. This basis is stated in the Quick Answer and again in the Conclusion section.
What business factors shaped Windlas Biotech Q2 Results FY27?
Ans. Revenue growth of 18.7%, net profit growth of 1.4% and four straight quarters of rising revenue are the factors reported for the quarter. The Key Business Factors section sets each one out.
What are the key risks after Windlas Biotech Q2 Results FY27?
Ans. The risks listed are a net profit margin of 6.8%, return on capital employed of 16.06% and return on equity of 12.52% in FY26. The Key Risks section describes each of them.
What is the outlook after Windlas Biotech Q2 Results?
Ans. The FY27 outlook depends on the figures reported in the coming quarters, since the quarter showed higher revenue and profit year on year. The Outlook section explains what investors can track.
Where can I find the complete Windlas Biotech Q2 Results FY27 data?
Ans. The complete data sits in the Financial Highlights table near the top of this article, which compares each line with the same quarter last year. The Univest app also carries the standalone results.
